ストックスクリーナーアプリを入手
7.75
0.00%
0.06
前日終値:
$7.69
開ける：
$7.76
24時間の取引高:
787
Relative Volume:
0.03
時価総額：
$16.86M
収益：
-
当期純損益:
$-563.30K
株価収益率:
-38.83
EPS:
-0.1996
ネットキャッシュフロー:
$-22.23M
1週間 パフォーマンス:
+12.67%
1か月 パフォーマンス:
-2.72%
6か月 パフォーマンス:
-24.72%
1年 パフォーマンス:
-71.25%
1日の値動き範囲:
$7.75
$7.835
1週間の範囲:
$6.72
$8.04
52週間の値動き範囲:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
名前
Promis Neurosciences Inc
セクター
電話
416-847-6898
住所
SUITE 200, 1920 YONGE STREET, TORONTO
PMN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
7.835 | 16.55M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.82 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
798.82 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.23 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.92 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.43 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Promis Neurosciences Inc (PMN) 最新ニュース
ProMIS Neurosciences regains Nasdaq compliance - MSN
ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Guidance Update: Will ProMIS Neurosciences Inc. (23J0) stock see valuation expansionWeekly Profit Summary & Community Consensus Trade Signals - Улправда
Will ProMIS Neurosciences Inc. (23J0) stock see valuation expansion2025 Volatility Report & Daily Entry Point Trade Alerts - Улправда
Why ProMIS Neurosciences Inc. (23J0) stock could outperform next yearQuarterly Trade Summary & Consistent Profit Trade Alerts - Улправда
Why ProMIS Neurosciences Inc. stock appeals to dividend seekers2025 Volume Leaders & Fast Momentum Stock Entry Tips - DonanımHaber
Why ProMIS Neurosciences Inc. stock remains on watchlistsGold Moves & Safe Capital Growth Plans - DonanımHaber
ProMIS Neurosciences completes enrollment for Alzheimer’s drug trial By Investing.com - Investing.com South Africa
ProMIS Neurosciences (PMN) Completes Patient Enrollment for Alzh - GuruFocus
ProMIS Neurosciences completes enrollment for Alzheimer’s drug trial - Investing.com
ProMIS Neurosciences exceeds target enrollment in Precise-AD phase 1b clinical trial - marketscreener.com
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease - The Manila Times
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 ... - Caledonian Record
ProMIS Neurosciences regains Nasdaq compliance with minimum bid price rule - Investing.com Australia
ProMIS Neurosciences Regains Nasdaq Compliance - TipRanks
ProMIS Neurosciences regains Nasdaq compliance with minimum bid price rule By Investing.com - Investing.com South Africa
ProMIS Neurosciences Announces Third Quarter 2019 Results - PR Newswire
ProMIS Neurosciences announces publication highlighting PMN310 - MSN
Cash per share of ProMIS Neurosciences Inc. – DUS:23J - TradingView — Track All Markets
ProMIS Neurosciences shareholders approve share consolidation proposal By Investing.com - Investing.com Nigeria
ProMIS Neurosciences shareholders approve share consolidation proposal - Investing.com
ProMIS Neurosciences (PMN) Reveals Promising Study Results for A - GuruFocus
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - The Manila Times
ProMIS Neurosciences Announces New Peer-Reviewed - GlobeNewswire
Fortrea (NASDAQ:FTRE) & Promis Neurosciences (NASDAQ:PMN) Head-To-Head Review - Defense World
ProMIS Neurosciences: Buy Rating Backed by Innovative EpiSelect™ Platform and Promising PMN310 Candidate - TipRanks
Pretax income of ProMIS Neurosciences Inc. – BER:23J - TradingView
ProMIS Neurosciences (PMN) Price Target Increased by 2,288.89% to 137.06 - Nasdaq
Can ProMIS Neurosciences Inc. (23J0) stock sustain margin levelsJuly 2025 Closing Moves & Weekly Top Gainers Alerts - Newser
HC Wainwright Has Strong Forecast for PMN FY2025 Earnings - Defense World
How strong is ProMIS Neurosciences Inc. (23J0) stock earnings growth2025 Institutional Moves & Weekly Breakout Watchlists - Newser
How geopolitical risks impact ProMIS Neurosciences Inc. (23J0) stock2025 Market Trends & Long-Term Growth Stock Strategies - Newser
ProMIS Neurosciences announces publication on plasma pTau in Alzheimer’s - MSN
ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright - MSN
ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN
Why hedge funds are buying ProMIS Neurosciences Inc. stockWeekly Trade Recap & AI Based Buy/Sell Signal Reports - Newser
symbol__ Stock Quote Price and Forecast - CNN
ProMIS Neurosciences stock rises after promising Alzheimer’s research data By Investing.com - Investing.com Australia
HC Wainwright & Co. Maintains ProMIS Neurosciences (PMN) Buy Recommendation - Nasdaq
ProMIS Neurosciences Inc (23J0.DU) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
PMN: HC Wainwright & Co. Raises Price Target and Maintains Buy R - GuruFocus
ProMIS Neurosciences (PMN) Sees Revised Price Target from H.C. W - GuruFocus
ProMIS Neurosciences stock rises after promising Alzheimer’s research data - Investing.com
Promis Neurosciences Inc (PMN) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
大文字化:
|
ボリューム (24 時間):